[The effect of l-DOPA on the development of neurogenic dystrophies].
D000818:Animals; D001808:Blood Vessels / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D001927:Brain Diseases / Q000378:metabolism / Q000517:prevention & control*; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004558:Electric Stimulation; D005753:Gastric Mucosa / Q000378:metabolism; D006331:Heart Diseases / Q000378:metabolism / Q000517:prevention & control*; D007773:Lactates / Q000378:metabolism; D008107:Liver Diseases / Q000517:prevention & control*; D008168:Lung / Q000378:metabolism; D008171:Lung Diseases / Q000378:metabolism / Q000517:prevention & control*; D008297:Male; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D011817:Rabbits; D051381:Rats; D012019:Reflex Sympathetic Dystrophy / Q000378:metabolism / Q000517:prevention & control*; D013272:Stomach Diseases / Q000378:metabolism / Q000517:prevention & control*; D013997:Time Factors; D014652:Vascular Diseases / Q000378:metabolism / Q000517:prevention & control*
D007773:Lactates; D004295:Dihydroxyphenylalanine; D009638:Norepinephrine
Vliianie l-DOFA na razvitie neĭrogennykh distrofiĭ.